Baxter looks to bring Immuno fibrin sealant to U.S. market following $715 mil. acquisition.
This article was originally published in The Gray Sheet
Executive Summary
BAXTER/IMMUNO COMBO COULD PROVIDE FIBRIN SEALANT TO U.S. MARKET, Baxter indicated during an Aug. 29 teleconference. The conference call followed the announcement by Baxter International and Orth, Austria-based Immuno International AG that Baxter will acquire the plasma derived medical products company over a period of three years for approximately $715 mil.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.